Alterations in PARK2 are highly common in human cancers, and the gene product of PARK2, the ubiquitin E3 ligase Parkin, has been shown to inhibit both NF‐κB and PI3K/AKT signalling and is a key activator for the cell death pathway induced by TNFR1 and its ligands [26, 27, 28]. This evidence concerns the gene NFKB1 and cancer.